GLP-1 medications and the evolving science of longevity

Medical discussions regarding longevity are shifting focus from merely extending lifespan to preserving autonomy and quality of life. A significant area of research involves GLP-1 agonists, commonly known as weight-loss medications, and their potential role in preventing age-related diseases.

While science has primarily confirmed that these medications can indirectly extend life by reducing diseases associated with obesity, research is ongoing into whether they can directly impact the biological aging process. The market for appetite regulators is substantial, with estimates suggesting it could reach R$ 50 billion by 2030, potentially serving 15 million users.